Anxiolytic drugs
Upcoming SlideShare
Loading in...5
×
 

Anxiolytic drugs

on

  • 1,781 views

 

Statistics

Views

Total Views
1,781
Views on SlideShare
1,777
Embed Views
4

Actions

Likes
1
Downloads
106
Comments
0

1 Embed 4

http://study.myllps.com 4

Accessibility

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Anxiolytic drugs Anxiolytic drugs Presentation Transcript

  • SEDATIVE/HYPNOTICS ANXIOLYTICS Martha I. Dávila-García, Ph.D. Howard University Department of Pharmacology
  • Optimal Performance NervousPerformance Sedated Breakdown Anxiety GOAL
  • Normal  Relief from Anxiety_________  _________________ SEDATION (Drowsiness/decrease reaction time)  HYPNOSIS  Confusion, Delirium, Ataxia  Surgical Anesthesia  Depression of respiratory and vasomotor center in the brainstem COMA  DEATH
  • SEDATIVE/HYPNOTICS ANXIOLYTICS• Major therapeutic use is to relief anxiety (anxiolytics) or induce sleep (hypnotics).• Hypnotic effects can be achieved with most anxiolytic drugs just by increasing the dose.• The distinction between a "pathological" and "normal" state of anxiety is hard to draw, but in spite of, or despite of, this diagnostic vagueness, anxiolytics are among the most prescribed substances worldwide.
  • Manifestations of anxiety:• Verbal complaints. The patient says he/she is anxious, nervous, edgy.• Somatic and autonomic effects. The patient is restless and agitated, has tachycardia, increased sweating, weeping and often gastrointestinal disorders.• Social effects. Interference with normal productive activities.
  • Pathological AnxietyGeneralized anxiety disorder (GAD): People suffering from GAD have general symptoms of motor tension, autonomic hyperactivity, etc. for at least one month.Phobic anxiety: Simple phobias. Agoraphobia, fear of animals, etc. Social phobias.Panic disorders: Characterized by acute attacks of fear as compared to the chronic presentation of GAD.Obsessive-compulsive behaviors: These patients show repetitive ideas (obsessions) and behaviors (compulsions).
  • Causes of Anxiety1). Medical: o Respiratory o Endocrine o Cardiovascular o Metabolic o Neurologic.
  • Causes of Anxiety2). Drug-Induced: – Stimulants • Amphetamines, cocaine, TCAs, caffeine. – Sympathomimetics • Ephedrine, epinephrine, pseudoephedrine phenylpropanolamine. – AnticholinergicsAntihistaminergics • Trihexyphenidyl, benztropine, meperidine diphenhydramine, oxybutinin. – Dopaminergics • Amantadine, bromocriptine, L-Dopa, carbid/levodopa.
  • Causes of Anxiety – Miscellaneous: • Baclofen, cycloserine, hallucinogens, indomethacin.3). Drug Withdrawal: • BDZs, narcotics, BARBs, other sedatives, alcohol.
  • AnxiolyticsStrategy for treatmentReduce anxiety without causing sedation.
  • Anxiolytics • Benzodiazepines (BZDs). • Barbiturates (BARBs). • 5-HT1A receptor agonists. • 5-HT2A, 5-HT2C & 5-HT3 receptor antagonists.If ANS symptoms are prominent: • ß-Adrenoreceptor antagonists. ∀ α2-AR agonists (clonidine).
  • Anxiolytics• Other Drugs with anxiolytic activity. – TCAs (Fluvoxamine). Used for Obsessive compulsive Disorder. – MAOIs. Used in panic attacks. – Antihistaminic agents. Present in over the counter medications. – Antipsychotics (Ziprasidone).• Novel drugs. (Most of these are still on clinical trials). – CCKB (e.g. CCK4). – EAAs/NMDA (e.g. HA966).
  • Sedative/Hypnotics• A hypnotic should produce, as much as possible, a state of sleep that resembles normal sleep.
  • Sedative/Hypnosis• By definition all sedative/hypnotics will induce sleep at high doses.• Normal sleep consists of distinct stages, based on three physiologic measures: electroencephalogram, electromyogram, electronystagmogram. Two distinct phases are distinguished which occur cyclically over 90 min:1) Non-rapid eye movement (NREM). 70-75% of total sleep. 4 stages. Most sleep  stage 2.2) Rapid eye movement (REM). Recalled dreams.
  • Properties of Sedative/Hypnotics in Sleep1) The latency of sleep onset is decreased (time to fall asleep).2) The duration of stage 2 NREM sleep is increased.3) The duration of REM sleep is decreased.4) The duration of slow-wave sleep (when somnambulism and nightmares occur) is decreased.Tolerance occurs after 1-2 weeks.
  • Other Properties of Sedative/Hypnotics• Some sedative/hypnotics will depress the CNS to stage III of anesthesia.• Due to their fast onset of action and short duration, barbiturates such as thiopental and methohexital are used as adjuncts in general anesthesia.
  • Sedative/Hypnotics1) Benzodiazepines (BZDs): Alprazolam, diazepam, oxacepam, triazolam2) Barbiturates: Pentobarbital, phenobarbital3) Alcohols: Ethanol, chloral hydrate, paraldehyde, trichloroethanol,4) Imidazopyridine Derivatives: Zolpidem5) Pyrazolopyrimidine Zaleplon
  • Sedative/Hypnotics6) Propanediol carbamates: Meprobamate7) Piperidinediones Glutethimide5) Azaspirodecanedione Buspirone9) β-Blockers** Propranolol10) α2-AR partial agonist** Clonidine
  • Sedative/HypnoticsOthers:11) Antyipsychotics ** Ziprasidone12) Antidepressants ** TCAs, SSRIs13) Antihistaminic drugs ** Dephenhydramine
  • Sedative/Hypnotics All of the anxiolytics/sedative/hypnoticsshould be used only for symptomatic relief. *************All the drugs used alter the normal sleep cycle and should be administered only for days or weeks, never for months. ************ USE FORSHORT-TERM TREATMENT ONLY!!
  • Sedative/Hypnotics Relationship between Older vs Newer DrugsBarbiturates BenzodiazepinesGlutethimide ZolpidemMeprobamate Zaleplon**All others differ in their effects and therapeuticuses. They do not produce general anesthesiaand do not have abuse liability.
  • SEDATIVE/HYPNOTICS ANXYOLITICSB E N Z O D IA Z E P IN E S B A R B IT U R A T E S GABAergic SYSTEM
  • Sedative/HypnoticsThe benzodiazepines are the most important sedative hypnotics.Developed to avoid undesirable effects of barbiturates (abuse liability).
  • Benzodiazepines • Diazepam • Chlordiazepoxide • Triazolam • Lorazepam • Alprazolam• Clorazepate => nordiazepam • Halazepam • Clonazepam • Oxazepam • Prazepam
  • Barbiturates• Phenobarbital• Pentobarbital• Amobarbital• Mephobarbital• Secobarbital• Aprobarbital
  • NORMAL  ANXIETY_________  _________________ SEDATION  HYPNOSIS  Confusion, Delirium, Ataxia  Surgical Anesthesia  COMA  DEATH
  • Respiratory Depression BARBS BDZs Coma/ AnesthesiaRESPONSE Ataxia ETOH Sedation Anticonvulsant Anxiolytic DOSE
  • Respiratory Depression BARBS Coma/ BDZs AnesthesiaRESPONSE Ataxia Sedation Anticonvulsant Anxiolytic DOSE
  • GABAergic SYNAPSEglucose glutamate GAD GABA - Cl
  • GABA-A Receptor • Oligomeric (αβδγεπρ) glycoprotei BDZs n.BARBs • Major player in GABA AGONISTS Inhibitory Synapses. • It is a Cl- Channel. γ • Binding of GABA α causes the channel δ to open and Cl- to β ε flow into the cell with the resultant membrane hyperpolarization.
  • Mechanisms of Action1) Enhance GABAergic Transmission  frequency of openings of GABAergic channels. Benzodiazepines  opening time of GABAergic channels. Barbiturates  receptor affinity for GABA. BDZs and BARBS2) Stimulation of 5-HT1A receptors.3) Inhibit 5-HT2A, 5-HT2C, and 5-HT3 receptors.
  • Patch-Clamp Recording of SingleChannel GABA Evoked Currents From Katzung et al., 1996
  • BenzodiazepinesPHARMACOLOGY• BDZs potentiate GABAergic inhibition at all levels of the neuraxis.• BDZs cause more frequent openings of the GABA-Cl- channel via membrane hyperpolarization, and increased receptor affinity for GABA.• BDZs act on BZ1 (α1 and α2 subunit-containing) and BZ2 (α5 subunit-containing) receptors.• May cause euphoria, impaired judgement, loss of cell control and anterograde amnesic effects.
  • Pharmacokinetics of Benzodiazepines• Although BDZs are highly protein bound (60-95%), few clinically significant interactions.*• High lipid solubility  high rate of entry into CNS  rapid onset.*The only exception is chloral hydrate and warfarin
  • CNS Effects (Rate of Onset)Lipid solubility
  • Pharmacokinetics of Benzodiazepines• Hepatic metabolism. Almost all BDZs undergo microsomal oxidation (N- dealkylation and aliphatic hydroxylation) and conjugation (to glucoronides).• Rapid tissue redistribution  long acting  long half lives and elimination half lives (from 10 to > 100 hrs).• All BDZs cross the placenta  detectable in breast milk  may exert depressant effects on the CNS of the lactating infant.
  • Pharmacokinetics of Benzodiazepines• Many have active metabolites with half- lives greater than the parent drug.• Prototype drug is diazepam (Valium), which has active metabolites (desmethyl- diazepam and oxazepam) and is long acting (t½ = 20-80 hr).• Differing times of onset and elimination half-lives (long half-life => daytime sedation).
  • Biotransformation of Benzodiazepines From Katzung, 1998
  • Biotransformation of Benzodiazepines• Keep in mind that with formation of active metabolites, the kinetics of the parent drug may not reflect the time course of the pharmacological effect.• Estazolam, oxazepam, and lorazepam, which are directly metabolized to glucoronides have the least residual (drowsiness) effects.• All of these drugs and their metabolites are excreted in urine.
  • Properties of Benzodiazepines• BDZs have a wide margin of safety if used for short periods. Prolonged use may cause dependence.• BDZs have little effect on respiratory or cardiovascular function compared to BARBS and other sedative-hypnotics.• BDZs depress the turnover rates of norepinephrine (NE), dopamine (DA) and serotonin (5-HT) in various brain nuclei.
  • Side Effects of Benzodiazepines• Related primarily to the CNS depression and include: drowsiness, excess sedation, impaired coordination, nausea, vomiting, confusion and memory loss. Tolerance develops to most of these effects.• Dependence with these drugs may develop.• Serious withdrawal syndrome can include convulsions and death.
  • Sedative/Hypnotics• They produce a pronounce, graded, dose-dependent depression of the central nervous system.
  • Toxicity/Overdose with Benzodiazepines• Drug overdose is treated with flumazenil (a BDZ receptor antagonist, short half-life), but respiratory function should be adequately supported and carefully monitored.• Seizures and cardiac arrhythmias may occur following flumazenil administration when BDZ are taken with TCAs.• Flumazenil is not effective against BARBs overdose.
  • Drug-Drug Interactions with BDZs• BDZs have additive effects with other CNS depressants (narcotics), alcohol => have a greatly reduced margin of safety.• BDZs reduce the effect of antiepileptic drugs.• Combination of anxiolytic drugs should be avoided.• Concurrent use with ODC antihistaminic and anticholinergic drugs as well as the consumption of alcohol should be avoided.• SSRI’s and oral contraceptives decrease metabolism of BDZs.
  • Pharmacokinetics of Barbiturates• Rapid absorption following oral administration.• Rapid onset of central effects.• Extensively metabolized in liver (except phenobarbital), however, there are no active metabolites.• Phenobarbital is excreted unchanged. Its excretion can be increased by alkalinization of the urine.
  • Pharmacokinetics of Barbiturates• In the elderly and in those with limited hepatic function, dosages should be reduced.• Phenobarbital and meprobamate cause autometabolism by induction of liver enzymes.
  • Properties of BarbituratesMechanism of Action. • They increase the duration of GABA-gated channel openings. • At high concentrations may be GABA- mimetic. Less selective than BDZs, they also: • Depress actions of excitatory neurotransmitters. • Exert nonsynaptic membrane effects.
  • Toxicity/Overdose• Strong physiological dependence may develop upon long-term use.• Depression of the medullary respiratory centers is the usual cause of death of sedative/hypnotic overdose. Also loss of brainstem vasomotor control and myocardial depression.
  • Toxicity/Overdose• Withdrawal is characterized by increase anxiety, insomnia, CNS excitability and convulsions.• Drugs with long-half lives have mildest withdrawal (.• Drugs with quick onset of action are most abused.• No medication against overdose with BARBs.• Contraindicated in patients with porphyria.
  • Sedative/HypnoticsTolerance and excessive rebound occur in response to barbiturate hypnotics. SLEEP PER NIGHT CONTROL WITHDRAWAL (%) REM NREM III and IV 1 2 3 NIGTHS OF DRUG DOSING
  • Miscellaneous Drugs• Buspirone• Chloral hydrate• Hydroxyzine• Meprobamate (Similar to BARBS)• Zolpidem (BZ1 selective)• Zaleplon (BZ1 selective)
  • BUSPIRONE• Most selective anxiolytic currently available.• The anxiolytic effect of this drug takes several weeks to develop => used for GAD.• Buspirone does not have sedative effects and does not potentiate CNS depressants.• Has a relatively high margin of safety, few side effects and does not appear to be associated with drug dependence.• No rebound anxiety or signs of withdrawal when discontinued.
  • BUSPIRONESide effects: • Tachycardia, palpitations, nervousness, GI distress and paresthesias may occur. • Causes a dose-dependent pupillary constriction.
  • BUSPIRONEMechanism of Action: • Acts as a partial agonist at the 5-HT1A receptor presynaptically inhibiting serotonin release. • The metabolite 1-PP has α2 -AR blocking action.
  • Pharmacokinetics of BUSPIRONE• Not effective in panic disorders.• Rapidly absorbed orally.• Undergoes extensive hepatic metabolism (hydroxylation and dealkylation) to form several active metabolites (e.g. 1-(2- pyrimidyl-piperazine, 1-PP)• Well tolerated by elderly, but may have slow clearance.• Analogs: Ipsapirone, gepirone, tandospirone.
  • Zolpidem• Structurally unrelated but as effective as BDZs.• Minimal muscle relaxing and anticonvulsant effect.• Rapidly metabolized by liver enzymes into inactive metabolites.• Dosage should be reduced in patients with hepatic dysfunction, the elderly and patients taking cimetidine.
  • Properties of ZolpidemMechanism of Action: • Binds selectively to BZ1 receptors. • Facilitates GABA-mediated neuronal inhibition. • Actions are antagonized by flumazenil
  • GABA (-) (-) (-) (-) (-) ACh ? NE DA 5-HTANTICONVULSANT/ ANXIOLYTIC ? SEDATION ?
  • Properties of Other drugs.• Chloral hydrate• Is used in institutionalized patients. It displaces warfarin (anti-coagulant) from plasma proteins.• Extensive biotransformation.
  • Properties of Other Drugsα2-Adrenoreceptor Agonists (eg. Clonidine)• Antihypertensive.• Has been used for the treatment of panic attacks.• Has been useful in suppressing anxiety during the management of withdrawal from nicotine and opioid analgesics.• Withdrawal from clonidine, after protracted use, may lead to a life-threatening hypertensive crisis.
  • Properties of Other Drugsβ-Adrenoreceptor Antagonists (eg. Propranolol) • Use to treat some forms of anxiety, particularly when physical (autonomic) symptoms (sweating, tremor, tachycardia) are severe. • Adverse effects of propranolol may include: lethargy, vivid dreams, hallucinations.
  • OTHER USES1. Generalized Anxiety Disorder Diazepam, lorazepam, alprazolam, buspirone2. Phobic Anxiety a. Simple phobia. BDZs b. Social phobia. BDZs3. Panic Disorders TCAs and MAOIs, alprazolam4. Obsessive-Compulsive Behavior Clomipramine (TCA), SSRI’s5. Posttraumatic Stress Disorder (?) Antidepressants, buspirone
  • Other Properties of Sedative/Hypnotics• BDZs on the other hand, with their long half-lives and formation of active metabolites, may contribute to persistent postanesthetic respiratory depression.• Most sedative/hypnotics may inhibit the development and spread of epileptiform activity in the CNS.• Inhibitory effects on multisynaptic reflexes, internuncial transmission and at the NMJ.
  • ANXYOLITICS HYPNOTICS Alprazolam Chloral hydrateChlordiazepoxide Estazolam Buspirone Flurazepam Diazepam Pentobarbital Lorazepam Lorazepam Oxazepam Quazepam Triazolam Triazolam Phenobarbital Secobarbital Halazepam Temazepam Prazepam Zolpidem
  • References:• Katzung, B.G. (2001) Basic and Clinical Pharmacology. 7th ed. Appleton and Lange. Stamford, CT.• Brody, T.M., Larner,J., and Minneman, K.P. (1998) Human Pharmacology: Molecular to Clinical. 2nd ed. Mosby-Year Book Inc. St. Louis, Missouri.• Rang, H.P. et al. (1995) Pharmacology . Churchill Livingston. NY., N.Y.• Harman, J.G. et al. (1996) Goodman and Gilmans The Pharmacological Basis of Therapeutics. 9th ed. McGraw Hill.